

Genital Herpes R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/GB8E48F01800EN.html>

Date: October 2020

Pages: 128

Price: US\$ 1,699.00 (Single User License)

ID: GB8E48F01800EN

Abstracts

Genital Herpes Pipeline Overview

The Q4 Genital Herpes pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Genital Herpes, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Genital Herpes Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Genital Herpes disease overview, Genital Herpes types, Genital Herpes symptoms, causes, and FDA/EMA approved treatment options.

Genital Herpes Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Genital Herpes indication. The report presents near-term and long-term pipeline development trends and potential insights.

Genital Herpes Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 28 companies. Business profiles and contact details of the companies actively perusing Genital Herpes pipeline are assessed.

Genital Herpes R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Genital Herpes discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Genital Herpes companies look for licensing and collaboration partners. High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Genital Herpes pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Genital Herpes Pipeline Market News and Developments during 2020

The Genital Herpes industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Genital Herpes Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Genital Herpes pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

28 companies are included including Abivax SA, AiCuris GmbH & Co KG, Anteris Technologies Ltd, Astellas Pharma Inc, Auritec Pharmaceuticals Inc,

Biomere LLC, BlueWillow Biologics, Brandenburg Antiinfektiva GmbH, Johnson & Johnson, NanoViricides Inc, Profectus BioSciences Inc, Rational Vaccines Inc, Redbiotec AG, Sanofi, Shulov Innovative Science Ltd, SL VaxiGen Inc, Squarex LLC, Starpharma Holdings Ltd, Stealth Biologics LLC, Thyreos LLC, United BioPharma Inc, Vaccibody AS, Vaxart Inc, Vaxxit Srl, Vir Biotechnology Inc, Viramatix Sdn Bhd, Vironova Medical AB, X-Vax Technology Inc,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Genital Herpes pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GENITAL HERPES PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Genital Herpes Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Genital Herpes Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Genital Herpes pipeline
- 2.5 Active Companies Developing Genital Herpes pipeline

3. GENITAL HERPES DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. GENITAL HERPES PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

- 4.1 Abivax SA
 - AiCuris GmbH & Co KG
 - Anteris Technologies Ltd
 - Astellas Pharma Inc
 - Auritec Pharmaceuticals Inc
 - Biomere LLC
 - BlueWillow Biologics
 - Brandenburg Antiinfektiva GmbH
 - Johnson & Johnson
 - NanoViricides Inc
 - Profectus BioSciences Inc
 - Rational Vaccines Inc
 - Redbiotec AG

Sanofi
Shulov Innovative Science Ltd
SL VaxiGen Inc
Squarex LLC
Starpharma Holdings Ltd
Stealth Biologics LLC
Thyreos LLC
United BioPharma Inc
Vaccibody AS
Vaxart Inc
Vaxxit Srl
Vir Biotechnology Inc
Viramatix Sdn Bhd
Vironova Medical AB
X-Vax Technology Inc

5. GENITAL HERPES PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

5.2.1 Drug

5.2.2 Mechanism of Action

5.2.3 Phase

5.2.4 Co-Developer

5.2.5 Originator

5.2.6 Synonym

5.2.7 Route of Administration

5.2.8 Type of Molecule

5.2.9 Orphan Drug Status

5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details

6. GENITAL HERPES PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

7.1 About the Publisher

7.2 Sources and Research Methodology

I would like to order

Product name: Genital Herpes R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/GB8E48F01800EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB8E48F01800EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970